{"transactions":[{"id":2829433,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-26T23:35:22.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":90000,"derivative":{"exercise_price":23.57,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-21-014984","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919121014984/doc4.xml","form_type":"4"}},{"id":2829432,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-26T23:35:22.000Z","date":"2021-02-26","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2020."}],"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001209191-21-014984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919121014984/doc4.xml","form_type":"4"}},{"id":3241038,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-28T22:49:46.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":85000,"derivative":{"exercise_price":7.8,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-20-014100","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919120014100/doc4.xml","form_type":"4"}},{"id":3480583,"issuer":{"id":143144,"kind":"organization","name":"PDL BIOPHARMA, INC.","symbol":"PDLI"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-25T01:40:43.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":126050,"price":3,"value":378150.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date."}],"balance_after":126050,"derivative":{"exercise_price":3,"expiration_date":"2029-06-19","underlying":"Common stock","underlying_shares":126050},"source":{"system":"sec-edgar","filing":"0000882104-19-000073","document":"wf-form4_156142682613892.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882104/000088210419000073/wf-form4_156142682613892.xml","form_type":"4"}},{"id":3523620,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-05-16T22:43:58.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":45000,"derivative":{"exercise_price":10.8,"expiration_date":"2029-05-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-030616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119030616/doc4.xml","form_type":"4"}},{"id":3618742,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-04T23:32:12.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 48 equal monthly installments following the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":8.02,"expiration_date":"2029-02-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-015930","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/doc4.xml","form_type":"4"}},{"id":3618741,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2019-03-04T23:32:12.000Z","date":"2019-02-28","kind":"grant","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001209191-19-015930","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119015930/doc4.xml","form_type":"4"}},{"id":3895370,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-06-13T21:14:19.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan."}],"balance_after":20000,"derivative":{"exercise_price":4.25,"exercise_date":"2019-06-12","expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001615774-18-005229","document":"s110810_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577418005229/s110810_form4.xml","form_type":"4"}},{"id":3897536,"issuer":{"id":143144,"kind":"organization","name":"PDL BIOPHARMA, INC.","symbol":"PDLI"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2018-06-12T20:28:32.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":54348,"price":2.76,"value":150000.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc."}],"balance_after":214190,"source":{"system":"sec-edgar","filing":"0000882104-18-000064","document":"wf-form4_152883529550586.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882104/000088210418000064/wf-form4_152883529550586.xml","form_type":"4"}},{"id":3912296,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-05-31T22:29:04.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date of May 21, 2018, and 1/36th of the remaining shares subject to the option vesting each month."}],"balance_after":50000,"derivative":{"exercise_price":7.28,"expiration_date":"2028-05-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-18-034472","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118034472/doc4.xml","form_type":"4"}},{"id":4003240,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-03-09T20:36:11.000Z","date":"2016-02-25","kind":"exercise","acquired":false,"shares":650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001615774-18-001756","document":"s109300_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577418001756/s109300_form4.xml","form_type":"4"}},{"id":4003239,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-03-09T20:36:11.000Z","date":"2017-02-09","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001615774-18-001756","document":"s109300_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577418001756/s109300_form4.xml","form_type":"4"}},{"id":4003238,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-03-09T20:36:11.000Z","date":"2017-05-27","kind":"exercise","acquired":false,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":750},"source":{"system":"sec-edgar","filing":"0001615774-18-001756","document":"s109300_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577418001756/s109300_form4.xml","form_type":"4"}},{"id":4003237,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2018-03-09T20:36:11.000Z","date":"2016-02-25","kind":"exercise","acquired":true,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":3855,"source":{"system":"sec-edgar","filing":"0001615774-18-001756","document":"s109300_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577418001756/s109300_form4.xml","form_type":"4"}},{"id":4003236,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2018-03-09T20:36:11.000Z","date":"2017-02-09","kind":"exercise","acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":5855,"source":{"system":"sec-edgar","filing":"0001615774-18-001756","document":"s109300_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577418001756/s109300_form4.xml","form_type":"4"}},{"id":4003235,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2018-03-09T20:36:11.000Z","date":"2017-05-27","kind":"exercise","acquired":true,"shares":750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":6605,"source":{"system":"sec-edgar","filing":"0001615774-18-001756","document":"s109300_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577418001756/s109300_form4.xml","form_type":"4"}},{"id":4275231,"issuer":{"id":6169,"kind":"organization","name":"Tonix Pharmaceuticals Holding Corp.","symbol":"TNXP"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-21T21:00:41.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan."}],"balance_after":20000,"derivative":{"exercise_price":4.18,"exercise_date":"2018-06-20","expiration_date":"2027-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001615774-17-003294","document":"s106633_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1430306/000161577417003294/s106633_form4.xml","form_type":"4"}},{"id":4286289,"issuer":{"id":143144,"kind":"organization","name":"PDL BIOPHARMA, INC.","symbol":"PDLI"},"owners":[{"id":142163,"kind":"person","name":"Saks Samuel R","position":1,"cik":"0001365615","reported_name":"Saks Samuel R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2017-06-13T00:20:03.000Z","date":"2017-06-09","kind":"grant","acquired":true,"shares":60729,"price":2.47,"value":150000.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders."}],"balance_after":159842,"source":{"system":"sec-edgar","filing":"0000882104-17-000066","document":"wf-form4_149731318782655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882104/000088210417000066/wf-form4_149731318782655.xml","form_type":"4"}}]}